Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 20Recurrence 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 17Colorectal Neoplasms 16Lymphoma, Non-Hodgkin 15Melanoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 10Lung Neoplasms 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Carcinoma, Hepatocellular 9Adenocarcinoma 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8

Interventions

mogamulizumab 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × Lymphoma, T-Cell, Cutaneous × Clear all
NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Kyowa Kirin Co., Ltd.

Phase 3 Completed
372 enrolled 14 charts 1 FDA
DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡